



ASH CLINICAL PRACTICE GUIDELINES  
VENOUS THROMBOEMBOLISM (VTE)



# Optimal Management of Anticoagulant Therapy

## *Educational Slides Set*

American Society of Hematology 2021

### **Authors:**

Mario Luis Tejerina Valle, MD, Caja Petrolera de Salud - Bolivia

Juan Carlos Serrano Casas, MD, Universidad Central de Venezuela



# Clinical Guidelines

## American Society of Hematology 2021

# Guidelines for management of venous thromboembolism in Latin America

Ignacio Neumann, Ariel Izcovich, Ricardo Aguilar, Guillermo León Basantes, Patricia Casais, Cecilia Colorio, Cecilia Guillermo, Pedro Garcia Lazaro, Jaime Pereira, Luis Meillon, Suely Meireles Rezende, Juan Carlos Serrano, Mario Luis Tejerina Valle, Felipe Vera, Lorena Karzulovic, Gabriel Rada, Holger Schunemann.

Neumann I, Izcovich A, Aguilar R, et al. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America. *Blood Adv.* 2021;5(15):3032-3046.

ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America

Ignacio Neumann,<sup>1</sup> Ariel Izcovich,<sup>2</sup> Ricardo Aguilar,<sup>3</sup> Guillermo León Basantes,<sup>4</sup> Patricia Casais,<sup>5,6</sup> Cecilia C. Colorio,<sup>7</sup> María Cecilia Guillermo Eposito,<sup>8</sup> Pedro P. García Lázaro,<sup>9,10</sup> Luis A. Meillon-García,<sup>11</sup> Jaime Pereira,<sup>12</sup> Suely Meireles Rezende,<sup>13</sup> Juan Carlos Serrano,<sup>14</sup> Mario L. Tejerina Valle,<sup>15</sup> Felipe Vera,<sup>16</sup> Lorena Karzulovic,<sup>17</sup> Gabriel Rada,<sup>1</sup> and Holger Schünemann<sup>18</sup>

<sup>1</sup>Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; <sup>2</sup>Hospital Alemán, Buenos Aires, Argentina; <sup>3</sup>Servicio de Hematología, Complejo Hospitalario Dr. Amulfo Arias Madrid, Panama City, Panama; <sup>4</sup>Clinica Universitaria Colombia, Bogotá, Colombia; <sup>5</sup>Epidemiología Clínica y Evidencia, Instituto de Investigaciones en Salud Pública, Universidad de Buenos Aires, Buenos Aires, Argentina; <sup>6</sup>Centro de Hematología Pavlovsky, Buenos Aires, Argentina; <sup>7</sup>Fundación Favaloro, Buenos Aires, Argentina; <sup>8</sup>Hospital de Clinicas Dr. Manuel Quintana, Montevideo, Uruguay; <sup>9</sup>Faculty of Medicine, Universidad Privada Antenor Oregón, Trujillo, Peru; <sup>10</sup>Hospital Especializado Victor Lazarte Echegaray, Trujillo, Peru; <sup>11</sup>The ABC Medical Center, Mexico City, Mexico; <sup>12</sup>Department of Hematology and Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile; <sup>13</sup>Department of Internal Medicine, Faculty of Medicine Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; <sup>14</sup>Unidad Hematológica Especializada IPE, Quota, Colombia; <sup>15</sup>Caja Costarricense de Salud, La Paz, Bolivia; <sup>16</sup>School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom; <sup>17</sup>Department of Podiatry, Pontificia Universidad Católica de Chile, Santiago, Chile; and <sup>18</sup>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada

**Background:** Venous thromboembolism (VTE) is a common disease in Latin American settings. Implementing international guidelines in Latin American settings requires additional considerations.

**Objective:** The purpose of our study was to provide evidence-based guidelines about managing VTE for Latin American patients, clinicians, and decision makers.

**Methods:** We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)-ADOLPMENT method to adapt recommendations from 2 American Society of Hematology (ASH) VTE guidelines (Treatment of VTE and Anticoagulation Therapy). ASH and local hematology societies formed a guideline panel comprised of medical professionals from 10 countries in Latin America. Panelists prioritized 18 questions relevant for the Latin American context. A knowledge synthesis team updated evidence reviews of health effects conducted for the original ASH guidelines and summarized information about factors specific to the Latin American context (ie, values and preferences, resources, accessibility, feasibility, and impact on health equity).

**Results:** The panel agreed on 17 recommendations. Compared with the original guideline, 4 recommendations changed direction and 1 changed strength.

**Conclusions:** This guideline adaptation project highlighted the importance of contextualization of recommendations suggested by the changes to the original recommendations. The panel also identified 2 implementation priorities for the region: expanding the availability of home treatment and increasing the availability of direct oral anticoagulants (DOACs). The guideline panel made a conditional recommendation in favor of home treatment for individuals with deep venous thrombosis and a conditional recommendation for either home or hospital treatment for individuals with pulmonary embolism. In addition, a conditional recommendation was made in favor of DOACs over vitamin K antagonists for several populations.

### Introduction

#### Aim of these guidelines and specific objectives

The purpose of these guidelines is to provide evidence-based recommendations about the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) for the Latin American context. The



## Latin American ADOLOPMENT project

- The Latin American ADOLOPMENT project is a pilot collaborative effort of the following institutions
- Argentine Society of Hematology (SAH) Cecilia Colorio, MD
- Bolivian Society of Hematology and Hemotherapy (SBHH) Mario Luis Tejerina Valle, MD
- Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) Suely Meireles Rezende, MD PhD
- Chilean Society of Hematology Jaime Pereira, MD
- Peruvian Society of Hematology (SPH) Pedro García Lázaro, MD
- Society of Hematology of Uruguay (SHU) Cecilia Guillermo, MD
- Venezuelan Society of Hematology (SVH) Juan Carlos Serrano, MD
- Latin American Cooperative Group of Hemostasis and Thrombosis (CLAHT) Patricia Casais, MD
- Mexican Association of Hematology Luis Meillon MD
- Colombian Association of Hematology and Oncology Guillermo Basantes MD
- American Society of Hematology
- MacGRADE Center



GRADE-ADOLOPMENT is an explicit and systematic method to adopt, adapt or develop recommendations based on evidence starting from an existing recommendation developed under GRADE approach.



## ASH Clinical Practice Guidelines on VTE

1. VTE prevention in hospitalized surgical patients
2. VTE prevention in hospitalized medical patients
3. Acute VTE Treatment (DVT y PE)
4. **Optimum Management of Anticoagulation Therapy**
5. VTE Prevention and Treatment in cancer patients
6. Heparin-induced Thrombocytopenia (HIT)
7. Thrombophilia
8. Pediatric VTE
9. VTE in the context of pregnancy
10. VTE Diagnosis

## How are the ASH Guidelines developed?

### PANEL CONFIRMATION

Each panel was formed based on key criteria:

- Balanced experience (including disciplines beyond hematology and patients)
- Attention to COI minimization and management

### CLINICAL QUESTIONS

10 to 20 clinically relevant questions worked out on PICO format (population, intervention, comparison and outcome)

### EXAMPLE OF PICO QUESTION

Should antithrombotic agents be administered early or late to patients submitted to surgery?

### SYNTHESIS OF EVIDENCES

Analysis of evidence of each PICO question x systematic review of effects:

- Desirable and Undesirable Effects
- Use of Resources
- Feasibility
- Acceptability
- Accessibility
- Patient Values and Preferences

### RECORD OF RECOMMENDATIONS

Recommendations made by panel members based on evidences of all factors

***ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources, such as this slide set, derived from guidelines that require updating are removed from the ASH website.***

## How should patients and physicians use these guidelines?

	<b>STRONG Recommendation</b> ("The panel recommends ...")	<b>CONDITIONAL Recommendation</b> ("The panel suggests ...")
<b>For Patients</b>	Most individuals will be for the intervention	Most individuals will be for the intervention, but several will not.
<b>For Doctors</b>	Most individuals should receive intervention.	Different adequate options for different patients, depending on their values and preferences. Make use of shared decisions.



## Goals

1. By the end of this session, you will be prepared to:
2. Define the level of care and type of initial anticoagulation of VTE patients
3. Establish the anticoagulation period according to the VTE event, provoked or not provoked with or without recurrence, with new VTE events under anticoagulation
4. Determine the role of both scores of recurrence and D-dimer in provoked events.
5. Management of complications due to anticoagulation

## What is this chapter about?

Anticoagulants bring benefits (reduction in thrombus extension, mortal PE) and risks (potentially lethal hemorrhage)

Recognition and mitigation of the risks of damage from anticoagulants is achieved thru a management approach based on evidences

This chapter focus on the optimal management of anticoagulants for the prevention and treatment of TVE (after choosing the anticoagulant).



## Case 1: New deep venous thrombosis and acute pulmonary embolism

### Male - 58 years of age

- **Previous pathological history:** Post-Operative between right kneecap replacement (TKR), AHT, chronic ischemic cardiomyopathy, overweight (BMI 29)
- **Medication:** Losartan, Carvedilol, ASA 100 mg/day
- **Clinical Profile:** Chest pain for 24 hours associates to mild moderate dyspnoea. Pain on right leg, AT 110/77 mmHg, pulse 96/min, RF 24/min SO<sub>2</sub> 92%. Increase of volume and pain over the entire right inferior limb from the last 72, lab: Dimer- D elevated, normal renal and hepatic functions, Scan Duplex showed extensive DVT of femoral and right popliteal vein, Femoral DVT in Scan duplex. AngioTAC: Subsegmental Pulmonary embolism without Right Ventricular dysfunction on Echocardiogram.
- **Diagnosis:** Proximal Deep Vein Thrombosis complicated with pattern provoked pulmonary embolism

Considering his clinical condition of low risk and hemodynamic stability; How would you consider to conduct his treatment?

- a) Fibrinolytic therapy, hospitalized
  - b) Hospitalized treatment with the use of unfractionated heparin and then Warfarin
  - c) Outpatient management with the use of DOACs exclusively
  - d) Short hospitalization with LMWH, but outpatient management mainly and then DOAC or Warfarin according to availability
- C and D are correct



## Recommendations


For patients with PE and low complication risks, the Latin American Panel suggests **treatment at home or hospital treatment** (*conditional recommendation, based on a very low certainty of the evidence on the effects*).

Results (Quality of Evidence)	Relative Risk (95% CI)	Absolute Anticipated Effects (95% CI)	
		Risk with Hospitalized Treatment	Risk with Outpatient treatment
● Mortality	RR 0.33 (0.01 - 7.98)	6 per 1000	4 minus per 1000 (6 minus to 42 plus)
● PE	RR 2.95 (0.12-71.85)	0 per 1000	0 por 1000
● Proximal Symptomatic DVT	Not estimable	0 x 1000	0 x 1000 (0 x 1000)
● Greater Bleeding	RR 6.88 (0.36. - 134,1)	0 per 1000	0 x 1000

Evidence of low quality, therefore benefit/ damage is uncertain. The panel also considered:

- This recommendation is not applicable to patients with other major risk conditions that require hospitalization, limited support or none at home, cannot afford drugs or have a history of deficient non-compliance.
- High risk of bleeding may also need to start treatment at the hospital.
- The treatment at home may not be feasible in certain contexts due to health system limitations or insurance policy restrictions

Evidence Quality (GRADE):





# Pesi score for PE severity classification

Table 1: Original and simplified Pulmonary Embolism Severity Index (PESI).

Variable	PESI (a) Original Score	PESI (b) Simplified Score
Age > 80 years	Age in years	1
Male	+10	-
History of Cancer	+30	1
History of Heart Failure	+10	1 (c)
History of Chronic Pulmonary Disease	+10	
Pulse ≥ 110 beats /minute	+20	1
Systolic Arterial pressure < 100 mm Hg	+30	1
Respiratory Frequency ≥ 30 x min	+20	-
Temperature < 36°C	+20	-
Altered Mental Status*	+60	-
Arterial Oxygen Saturation < 90%*	+20	1

**Fibrinolysis in Acute Pulmonary Embolism in cases with clear haemodynamic instability**

**PATIENT CLASS I  
Low Risk**

The patient total punctuation is obtained by adding up patient age in year and the points of each predictor when present. The score corresponds to the following risk classes: class I (≤65 points), class II (66-85 points), class III (86-105 points), class IV (106-125 points) and class V (> 125 points). Patients under risk classes I and II are defined as of low risk. (b) A patient total score is obtained by adding up the points. The score is sorted out according to the following risk classes: 0 low risk, 1 or more high risk. Empty cells S indicate that variables have not been included. (c) Variables have been combined into one sole category of Chronic Cardiopulmonary Disease.

## Recommendation

For patients with con DVP or PE, the ASH Latin American Panel suggests **the use of DOAC over AVK** (*conditional recommendation, based on moderate certainty of evidences about the effects*).

### Evidences of Research

- There are no direct comparison trials between DOAC and HBPM on this indication
- Indirect Evidences: DOAC vs HBPM have been compared only on VTE prophylaxis trials on hip and knee replacements, where DOAC reduces the risk of DVT de TVP with no increase of bleeding.
- However, in prophylaxis for hospitalized medical patients, the use of DOAC increases bleeding if compared to HBPM

*Moderate Quality of evidence.*

*The Panel also considers that:*

- Patients well controlled and with no complications can remain with AVK.
- Cases de Novo may prefer DOAC with regards to safety, load of treatment, difficulties to monitor the INR.
- Increase vigilance for the risk of bleeding with DOAC, even more so when domiciled far away.

## Case 1 (Continued):

- The patient was started on oral Rivaroxaban 15 mg every 12 hours for 21 days, then received 20 mg day for the following 3 and 6 months
- On day 2 of treatment, there is substantial improvement of the respiratory condition, but with development of much pain and functional helplessness and evaluations highlight a pronounced extensive DVT throughout the femoral vein.
- Assessed for vascular surgery to decide on the approach

The patient is assessed for Vascular Surgery, and the following proposals are discussed in the clinical team meeting; Which one do you agree with?

- A. Perform immediate surgical thrombectomy
- B. Keep only anticoagulation with Rivaroxaban for 3 to 6 months, individualizing recurrence risk.
- C. Perform IV thrombolysis
- D. Perform catheter guided thrombolysis.



## Recommendation

In patients with extensive proximal DVT, the ASH Latin American Panel suggests **against the thrombolysis in addition to anticoagulation** (*conditional recommendation, based on low certainty of the evidence on the effects*).

Results (Quality of Evidence)	Relative Risk (95% CI)	Absolute Anticipated Effects (95% CI)	
		Risk with anticoagulant	Risk with anticoagulant + Thrombolysis
● Late Mortality	RR 0.89 (0.46 - 1.69)	High 67 per 1000	<b>7 minus per 1000</b> (7 minus to 36 plus)
● PE	RR 1.33 (0.71 to 2.46)	0 per 1000	<b>0 per 1000</b>
● Proximal symptomatic DVT	RR 0.99 (0.56 to 1.76)	High 130 x 1000	<b>1 minus x 1000</b> (57 minus to 99 plus)
● Post phlebotic syndrome	RR 0.71 (0.60 to 0.85)	High 563 per 1,000	<b>163 minus x 1000</b> (225 minus to 84 less )
● Leg ulcer	RR 0.75 (0.39 to 1.42)	High 30 per 1,000	<b>8 minus x 1000</b> (18 minus to 13 plus)

*Evidence of low quality, therefore benefit /damage is uncertain. The Panel also considered:*

- Thrombolysis to be reasonable in cases of DVT threatening limbs, with severe symptoms that do not improve with anticoagulation only and or with iliofemoral DVT with high risk of PFS and low-medium risk of
- To take in account basal risks, patient preference and access to experimented care.

Evidence Quality (GRADE): Low ● Moderate ● Strong ●



## Case 1: Summary

For patients with PE and low risk of complications, suggestion of treatment either at home or hospital, according to availability of resources.

In case of low-risk PE or DVT plan the use of DOAC over AVK, even if well controlled patients can be maintained with AVK, in both cases monitor the risk of bleeding.

Thrombolysis is not recommended in extensive proximal venous thrombolysis, for the prevention of postphlebitic syndrome.

## Case 2: Deep venous thrombosis not provoked with high risk of bleeding Woman - 40 years of age

- **Pathological History:** Recurrent gastric peptic ulcer disease
- **Medication:** Esomeprazol 40 mg day
- **Clinical Profile:** As she rises from bed in the morning, she notices the development of edema and pain in the left inferior limb, difficulty to walk. Dimer-D on 1550 ug/L Scan Duplex showed left Iliofemoral DVT. Started treatment with Enoxaparin for 5 days then she is kept on Warfarin
- Thrombophilia profile negative
- **Diagnosis:** Proximal Deep Venous Thrombosis unprovoked



Considering her current clinical condition how long would you consider to give anticoagulation with warfarin?

- A. I would give anticoagulation for 2 months
- B. I would give anticoagulation for 3 to 6 months only
- C. I would give anticoagulation extended to beyond 3 – 6 months and would assess for the risk of thrombotic recurrence and bleeding
- D. I would give her anticoagulation indefinitely



## Recommendation

For patients with unprovoked PE or DVT, the ASH Latin American Panel suggests to **keep anticoagulation indefinitely over the interruption after a period of 3 to 6 months** (*conditional recommendation based on the moderate certainty of the evidence on the effects*).


Results (Evidence Quality)	Relative Risk (95% CI)	Absolute Anticipated Effects (95% CI)	
		Risk with defined antithrombotic duration (12 months or less)	Risk with undefined antithrombotic duration
● Mortality	RR 0.75 (0.49 -1.13)	18 por 1,000	<b>5 minus per 1,000</b> (9 minus to 2 plus)
● PE	RR 0.29 (0.15 -0.56)	29 por 1,000	<b>21 minus per 1,000</b> (25 minus to 13 minus)
● Proximal symptomatic DVT.	RR 0.20 (0.12 to 0.34)	63 per 1,000	<b>50 minus por 1,000</b> (56 minus to 42 minus)
● Major Bleeding	RR 2.24 (1.49 to 3.35)	5 per 1,000	<b>6 plus por 1,000</b> (2 plus to 12 plus)

*Moderate evidence, so the panel considered that:*

- The individual risk of DVT recurrence, risk of bleeding, costs, access to follow up and monitoring should be considered, in addition to patient values and preferences.
- This recommendation is applied to patients with average risk of bleeding.
- The risk of bleeding may change with time, benefit vs risk of anticoagulation should be reassessed periodically.

● Evidence Quality (GRADE): Low    ● Moderate    ● Strong

## VTE – Recurrence Risk




## Stratification of the Recurrence Risk of VTE

High Risk	Moderate Risk	Low Risk
<ul style="list-style-type: none"><li>• VTE in the last 3 months</li><li>• Deficiency of protein C, protein S or antithrombin</li><li>• Antiphospholipid syndrome</li><li>• Multiple thrombophilic anomalies</li></ul>	<ul style="list-style-type: none"><li>• VTE in the last 3-12 months</li><li>• Heterozygous V Leiden Factor</li><li>• 20210 prothrombin mutation</li><li>• Recurrent VTE</li><li>• Active Cancer</li></ul>	<ul style="list-style-type: none"><li>• VTE &gt; 12 months before</li><li>• No other risk factors</li></ul>



Members of the medical team treating the patient discuss the possibility of using Dimer-D or recurrence clinical scores to guide the use of anticoagulation.

Do you think this is a valid approach?





## Recommendation

For patients with unprovoked PE of DVT, the Latin American Panel suggests to be **against** the use of Dimer - D or prognosis scores to guide the duration of the anticoagulation (*conditional recommendation based on low certainty on proofs of the effects*)

Results (Evidence Quality)	Relative Risk (95% CI)	Absolute Anticipated Effects (95% CI)	
		Riesgo con anticoagulación no guiada	Risk with anticoagulation guided by Dimer-D and scores
● Mortality	RR 1.06 (0.07 to 18.30)	1 per 1000	<b>1 plus per 1,000</b> (9 minus to 168 plus)
● PE	RR 0.16 (0.02 to 1.33)	10 per 1000	<b>8 minus por 1,000</b> (10 minus to 3 plus)
● Proximal Symptomatic DVT	HR 2.59 (1.90 to 3.52)	11 per 1000	<b>17 mas por 1000</b> (9 plus to 26 plus)
● Major Bleeding	RR 3.49 (0.14 to 84.76)	10 per 1000	<b>24 mas por 1,000</b> (8 minus to 813 plus)

### Evidence of low quality, uncertain benefits:

- Should guide towards recommendation 8, undefined anticoagulation is maintained with recurrence risk vs bleeding assessed with time
- Dimer-D only as part of a prognostic model may be useful to determine there is much indecision or difficult clinical situation.



## Continuación Caso 2

### Case 2 (continued)

The patient was kept on anticoagulation with warfarin within therapeutic INR range, but as of the 7 month shows thrombotic recurrence whilst under treatment.

What would be your anticoagulation strategy and for how long?

- A. I would increase the warfarin dose (INR 3 to 4) with indefinite anticoagulation
- B. I would change to DOAC within indefinite anticoagulation
- C. I would change to DOAC within definite period for a year assessing the recurrence risk
- D. I would recommend anticoagulation with HBPM, with re-assessment of causes of thrombosis, then defining what the most appropriate oral agent for indefinite use.

## Recommendation

For patients with DVT or PE during the VKA treatment, the ASH Latin American Panel suggests the use of LMWH over DOAC (conditional recommendation, based on a very low certainty of the evidence of the effects).

### Research Evidences

- There are no direct comparison trials between DOAC and HBPM in this indication
- Indirect Evidence: DOAC vs HBPM have been compared in VTE prophylaxis trials in hip and knee replacement, in which DOAC reduces the risk of DTV and there is no bleeding increase.
- However, prophylaxis in hospitalized medical patients, the use of DOAC increases bleeding when compared to HBPM

*Evidence of low quality, therefore the panel has also considered:*

- To appraise the vast experience in HBPM for prothrombotic conditions.
- Not to demonstrate AVK in suboptimal range. A better dose adjustment must be guaranteed.
- The need to explore the underlying causes of the recurrence under AVK
- Final selection based on the underlying cause, patient values and preferences, cost and viability of each alternative.

## Recommendation

For patients with unprovoked recurrent PE or DVT, the ASH Latin American Panel recommends to maintain indefinite anticoagulation over the its interruption after a period of 3 to 6 months (*strong recommendation, based on moderate certainty of the evidence on the effects*).

Results (Evidence Quality)	Riesgo Relativo (95% CI)	Anticipated Absolute Effects (95% CI)	
		Risk with defined duration anticoagulation (12 months or less)	Risk with undefined duration anticoagulation
● Mortality	RR 0.75 (0.49 to 1.13)	16 por 1000	<b>4 minus per 1,000</b> (8 minus to 2 plus)
● PE	RR 0.29 (0.15 to 0.56)	29 por 1000	<b>21 minus per 1,000</b> (25 minus to 13 minus)
● Proximal Symptomatic DVT	RR 0.20 (0.12 to 0.34)	63 por 1000	<b>50 minus per 1,000</b> (56 minus to 42 minus)
● Major Bleeding	RR 2.17 (1.40 to 3.35)	5 por 1000	<b>6 plus per 1,000</b> (2 plus to 12 plus)

**Strong evidence of Good quality, moderate certainty, the Benefit is clearer:**

- This recommendation assumes the average risk of bleeding, it cannot be applied in cases with high probability of hemorrhage.
- The risk of bleeding may change with time, so the balance between desirable and undesirable consequences of indefinite anticoagulation must be often re-assessed

● Evidence Quality (GRADE): Low    ● Moderate    ● Strong

## Recurrence Risk after suspending anticoagulation Observational Studies Data

### Event provoked by a transitory risk factor

- EVT recurrent = 4,2 per 100 patient-year
- PE recurrent = 1,9 per 100 patient-year
- DVT recurrent = 2,3 per 100 patient-year

### Unprovoked Event

- EVT recurrent = 7,4 per 100 patient-year
- PE recurrent = 3,3 per 100 patient-year
- DVT recurrent = 4,1 per 100 patient-year

### Event provoked by a chronic risk factor (cancer excluded)

- EVT recurrent = 9,7 per 100 patient-year
- PE recurrent = 4,4 per 100 patient-year
- DVT recurrent = 5,3 per 100 patient-year

### Recurrent Unprovoked Event

- EVT recurrent = 12 per 100 patient-year
- PE recurrent = 5,4 per 100 patient-year
- DVT recurrent = 6,6 per 100 patient-year

\* DVT and PE rates were calculated assuming that 45% of recurrent EVT are PE.

1. Heit, John A., Spencer, Frederick A., White, Richard H.. The epidemiology of venous thromboembolism. *Journal of Thrombosis and Thrombolysis*; 01/16 2016.

2. Nordstrom, M., Lindblad, B., Bergqvist, D., Kjellstrom, T.. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. *J Intern Med*; Aug 1992.

3. Oger, E.. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. *Thromb Haemost*; May 2000.

## Case 2: Summary

For patients with unprovoked or recurrent unprovoked DVT or PE, suggestion to maintain indefinite anticoagulation over its interruption after a period of 3 to 6 months

In cases of unprovoked PE or DVT, suggestion to oppose the use of Dimer-D or prognostic scores to guide the duration of the anticoagulation, except for some very complex situations

In patients with DVT or PE during the VKA treatment, suggestion to use LMWH over DOAC initially, while a more efficient anticoagulation is proposed.



## Caso 3. Complications due to anticoagulation

**Personal History:** Hypertension, Chronic Renal Failure (no dialysis). Has not attended medical control for 3 months.

**Clinical Profile:** Female patient, 58 years of age, on Warfarin for 1 month for prevention of recurrent unprovoked PTE. Goes to hospital complaining of headache, dizziness, vomit and difficulty to move around in those 6 previous hours. CAT of skull performed Subarachnoid hemorrhage Fisher 3 and the INR is 10.

**Diagnosis:** Subarachnoid hemorrhage, Warfarin intoxication, recurrent PTE



Your patient is in vital emergency, with Hemorrhagic Cerebrovascular Accident (HCVA) and warfarin overdose. What would be the initial management recommendation to approach this case?

- A. Discontinue warfarin
- B. Give plasma fresh frozen plasma
- C. Give Vitamin K 5 mg IV
- D. Use of Prothrombin complex concentrate
- E. B and D are correct



## Recommendation

For patients with potential lethal bleeding related to AVK during the VTE treatment, the ASH Latin American Panel **suggests the use of 4 factor PCC or PFC in addition to the interruption of AVK, according to local availability and clinical circumstances** (*conditional recommendation, based on a very low certainty of the evidence on the effects*).

Results (Evidence Quality)	Relative Risk (95% CI)	Anticipated Absolute Effects (95% CI)	
		Risk with Frozen Fresh Plasma	Risk with CCP
● Mortality	RR 0.92 (0.37 a 2.28)	124 per 1000	<b>10 minus per 1000</b> (78 minus to 159 plus )
● DVT (all)	RR 1.60 (0.70 to 3.62)	68 per 1000	<b>41 plus per 1000</b> (20 minus a 179 plus)
● Major Bleeding	RR 1.34 (0.78 to 2.29)	91 per 1000	<b>31 plus per 1000</b> (20 minus to 117 plus)

*Low quality evidence, therefore the panel also considered, (low certainty of the evidence on the effects) :*

- There is no substantial evidence in safety and efficacy of results between CCP and PFC.
- To consider the use of CCP in cases of heart failure and volume overload, in addition zones with high risk of pathogen transmission.
- We should favor the fastest option according to local availability and costs in Latin America.

Evidence Quality (GRADE): ● Low    ● Moderate    ● Strong





## Case 3 (continued)

The patient received successful surgical intervention, considering life threatening bleeding she had and the unprovoked recurrent thrombosis.

What would be your treatment strategy?

- A. Discontinue anticoagulant due to high risk of new bleeding
- B. Re-start oral anticoagulation once she has been clinically recovered between 15 and 90 days
- C. Recommend HBPM in one week
- D. Recommend AAS

## Recommendation

For patients that receive treatment to VET and survive a major bleeding episode related to the anticoagulation therapy, the ASH Latin American Panel suggests **to resume oral anticoagulation therapy upon interruption** (*conditional recommendation based on the very low certainty of the evidence on the effects*).

Resume vs interrupt anticoagulant treatment for VET in the wake of a major bleeding:

Results (Evidence Quality)	Relative Effect (95% CI)	Anticipated Absolute Effects (95% CI)	
		Risk with Discontinuation	Difference of Risk with resume of anticoagulation
● Mortality	<b>RR 0.59</b> (0.45 to 0.77)	845 of 2,455 (34.4%)	<b>141 less deaths per 1000</b> (79 minus to 189 plus)
● PE	<b>RR 0.26</b> (0.08 to 0.82)	12 of 425 (2.8%)	<b>21 less PE per 1000</b> ( 5 minus to 26 minus)
● Symptomatic Proximal DVT	<b>RR 0.66</b> (0.25 to 1.75)	11 of 464 (2.4%)	<b>8 less DVT per 1,000</b> (18 minus to 18 plus)
● Major Bleeding	<b>RR 1.54</b> (1.18 to 2.02)	230 of 3,304 (7.0%)	<b>38 more bleeding per 1000</b> (13 plus to 71 plus)

Increased risk of recurrent hemorrhage offset by an improvement on mortality due to all causes

Applied to patients that require anticoagulation for long or indefinitely.

Evidence Quality (GRADE): ● Low ● Moderate ● Strong

## Comments

- The decision to resume anticoagulation may vary according to the risk of recurrent PTE and the risk and severity of bleeding.
- An approach of decisions shared that explore values given by patients to the prevention of PTE or bleeding may be a form of implementing the recommendation.
- Time to resume anticoagulation remains unknown and it varies depending on particularities of each patient. It is reasonable to consider waiting for at least 2 weeks, but no longer than 90 days after the bleeding episode. However, anticoagulation should be considered to resume as early as possible if bleeding cause was identified and corrected.

## Case 3 (continued)

- Patient and family members, considering the hemorrhagic risk, discuss the possibility of using antithrombotic drug of lower hemorrhagic risk, she is not a candidate to DOAC due to renal failure,
- Debate about the possibility of aspirin 100 mg day.

Do you agree with this approach?

YES

NO



## Recommendation

Should Aspirin be used versus standard dose of anticoagulation in patients to whom an indefinite duration is preferred, after completing an initial anticoagulation course of defined duration (12 months or less). *(Conditional Recommendation, based on a moderate certainty of the evidence).*

Results (Evidence Quality)	Relative Risk (95% CI)	Anticipated Absolute Effects (95% CI)	
		Risk with standard anticoagulation	Risk with aspirin
● Mortality	RR 0.86 (0.31 to 2.35)	7 per 1000	<b>1 minus per 1000</b> <b>(5 minus to 10 plus)</b>
● PE	RR 3.10 (1.24 to 7.73)	5 per 1000	<b>11 plus per 1,000</b> <b>(1 mas a 36 mas)</b>
● Proximal Symptomatic DVT.	RR 3.15 (1.50 to 6.63)	8 per 1000	<b>17 plus per 1000</b> <b>(4 plus to 46 plus)</b>
● Major Bleeding	RR 0.49 (0.12 to 1.95)	5 per 1000	<b>3 menos</b> <b>per 1,000</b> <b>(5 minus to 5 plus)</b>

*Evidence with moderate certainty, the benefit is clearer:*

- Compared with long term anticoagulation , the treatment with Aspirin could increase the risk of VTE with all negative consequences (hospitalization costs, vs disease risks, etc.),
- The panel assumed that cost effectiveness favors long term anticoagulation.



Evidence Quality (GRADE): Low Moderate Strong



## Summary Case 3

For patients with potentially mortal bleeding related to AVK during the treatment of VTE, the use of 4 factor CCP or PFC is considered in addition to the interruption of AVK, according to local availability.

For patients with VTE who require indefinite anticoagulation, consider the possibility of resuming anticoagulation within 15 to 90 days after a major hemorrhagic episode.

For the use of long term antithrombotic agents, the use of Aspirin does not replace anticoagulants.

## Other Guide Recommendations not approached in this discussion.

- Thrombolysis in submassive PE based with eco or biomarkers compatible with the right ventricle dysfunction.
- Use of compression stockings by patients with DVT and high risk of post-thrombotic syndrome.
- Use of DOAC standard dose vs lower doses in long term anticoagulation
- Use of Aspirin in cardiovascular primary prevention associated with chronic anticoagulation
- Definition of anticoagulation in recurrent provoked events and with persistent chronic factors

**Those first 4 recommendations with low or very low certainty of the evidence**

## Summary

### Back to Goals

1. Define the attention level and type of initial anticoagulation of patients with VTE
  - Cases of low risk PE and DVT can be managed as out-patients, for initial anticoagulation ACOD, thrombolysis is not indicated for extensive DVT
2. Establish anticoagulation period in VTE, provoked and unprovoked with or without recurrence, with new VTE under anticoagulation
  - In unprovoked recurrent VTE guidance towards indefinite anticoagulation
3. Determine the Role of recurrence and Dimer-D scores in unprovoked events.
  - Not appropriate the use of Dimer-D and Score System to guide routine anticoagulation
4. Manage complications caused by anticoagulation
  - Both CCP and PFC can be used to reverse Warfarin anticoagulation, in the wake of a severe hemorrhagic event, it is suitable to restart anticoagulation between 15 and 90 days





## Gratitude

- Team members of the ASH Latin American Panel of Guidelines on VTE
- ASH Team Members
- GRADE Center - McMaster University
- ASH VTE Slide kit authors:
  - Mario Luis Tejerina Valle, MD, Caja Petrolera de Salud - Bolivia
  - Juan Carlos Serrano Casas, MD, Universidad Central de Venezuela

For more information on the **ASH Guidelines on VTE**: [www.hematology.org/VTE](http://www.hematology.org/VTE)